2013
DOI: 10.1111/jcmm.12000
|View full text |Cite
|
Sign up to set email alerts
|

PARP1 inhibition affects pleural mesothelioma cell viability and uncouples AKT/mTOR axis via SIRT1

Abstract: Malignant Pleural Mesothelioma (MMe) is a rare but increasingly prevalent, highly aggressive cancer with poor prognosis. The aetiology of MMe is essentially a function of previous exposure to asbestos fibres, which are considered to be an early-stage carcinogen. Asbestos is toxic to human mesothelial cells (HMCs), that activate the nuclear enzyme poly(ADP-ribose) polymerase-1 (PARP1) to repair DNA. The targeting of PARP1 is showing considerable potential for delivering selective tumour cell kill while sparing … Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
32
0

Year Published

2015
2015
2021
2021

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 34 publications
(33 citation statements)
references
References 41 publications
(46 reference statements)
1
32
0
Order By: Relevance
“…PARP inhibition by structurally different PARP inhibitors increases the activity of PI3K [35] and Akt [34][35][36] thus preventing the loss of the mitochondrial membrane potential upon oxidative damage [34]. Tankyrases are also likely to possess regulatory properties over mitochondria by interacting with GSK3 [37].…”
Section: Q2mentioning
confidence: 99%
“…PARP inhibition by structurally different PARP inhibitors increases the activity of PI3K [35] and Akt [34][35][36] thus preventing the loss of the mitochondrial membrane potential upon oxidative damage [34]. Tankyrases are also likely to possess regulatory properties over mitochondria by interacting with GSK3 [37].…”
Section: Q2mentioning
confidence: 99%
“…PARP-1 and PARP-2 regulate SIRT1 via different mechanisms. PARP-1 increase SIRT1 activity indirectly through the modulation of NAD + levels (Pinton et al, 2013). Instead, PARP-2 is found to bind directly to the SIRT1 proximal promoter where it acts to negatively regulate SIRT1 expression (Chung & Joe, 2014).…”
Section: Discussionmentioning
confidence: 99%
“…SIRTs affect these processes via the down-regulation of a serine/threonine kinase called mammalian target of rapamycin (mTOR) [8,9] and other intracellular signaling pathways [5], although mTOR can in turn up-regulate SIRTs production [9,10,11,12]. Recently, SIRTs and their regulators have been intensively studied to examine the potential of SIRTs to be diagnostic and predictive indexes for some disorders, and to be useful for the treatment of malignant and metabolic disorders.…”
Section: Introductionmentioning
confidence: 99%